GAITHERSBURG, Md., Feb. 14,
2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq:
YS) ("YS Biopharma" or the "Company", and together with its
subsidiaries, "YS Group"), a global biopharmaceutical company
dedicated to discovering, developing, manufacturing, and delivering
new generations of vaccines and therapeutic biologics for
infectious diseases and cancer, today announced the appointment of
six new members to its Board of Directors (the "Board"), effective
February 13, 2024. The six new
directors are: Dr. Yuntao Cui; Dr.
Jin Wang; Mr. Henry Chen; Mr. Haitao
Zhao; Mr. Pierson Yue Pan;
and Ms. Brenda Chunyuan Wu.
In addition to the new appointments, the Board has elected Dr.
Ajit Shetty, who had served as the
Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board,
effective February 13, 2024.
Dr. Yuntao Cui has over 15 years
of law-related work experience, and has previously worked as a
Senior Lawyer at Zhong Lun Law Firm, one of the top law firms in
China, and as General Manager of
Legal Affairs at Wanda Group, a top conglomerate in the real
estate, finance, and hospitality industries. Dr. Cui is currently a
Senior Vice President and General Counsel at Juventas Cell Therapy
Ltd., a leading immune cell therapy company. Dr. Cui holds a JD
from Renmin University of China.
Dr. Jin Wang is Founding Partner
and CEO of Manhattan Capital Investment Consulting Group ("MCG"),
and has managed the venture capital investment fund Nuokang Venture
Fund since 2014. Dr. Wang has more than 27 years of experience
finding, building, and strategizing for biotech companies,
including his co-founding and angel investment in leading medical
professional networking and service firm DXY. Dr. Wang previously
worked as an analyst and Asia/Greater China Regional Director for
Paramount Capital Investment, LLC, and co-founded the Sino-American
Pharmaceutical Professionals Association ("SAPA") in 1993. Dr. Wang
holds a PhD in Biomedical Science from Worcester Polytechnic Institute.
Mr. Henry Chen is the CEO of
Monument Pacific Development Corp., a California-based company dedicated to
developing, managing, and operating residential and commercial
properties in Northern and Southern
California. Mr. Chen received his MBA from the University of California, Berkeley's Hass School of Business in 2012, and a Bachelor
of Laws in Business Administration and Management from the
Beijing University of Chemical
Technology in 2005.
Mr. Haitao Zhao has served as a
Partner of the Shanxi Tie Niu law firm since 2016, where he is
responsible for handling corporate law related to intellectual
property protection, corporate internal governance, and
financing-related legal services. Previously, Mr. Zhao worked as an
Attorney for the Beijing Ding En law firm from 2012-2016. He holds
an MA in International Law from Shanxi University.
Mr. Pierson Yue Pan has served as
a Vice President of Monument Pacific Development Corp. since 2018.
Previously, Mr. Pan worked as Vice President of Project Development
at real estate developer Propriis from 2012-2018, and as General
Manager of the Africa Market with the China Civil Engineering
Construction Company Nigeria Limited from 2004-2011. Mr. Pan holds
an MBA from the University of California,
Berkeley's Hass School of
Business.
Ms. Chunyuan (Brenda) Wu
currently serves as the CFO of YS Group, a position she has held
since December 31, 2020. Previously, Ms. Wu served as CFO of
YS Group Biopharma from 2018-2020, and as Financial Controller for
the same company from 2013-2018. Ms. Wu has also previously worked
as a Senior Auditor at Ernst & Young. Ms. Wu holds degrees in
Accounting and Finance from Washington State
University.
Dr. Ajit Shetty, Chairperson of
the Board of Directors of the Company, commented, "We are pleased
to welcome each of our new directors to the Board. Each of these
talented individuals brings valuable expertise in various aspects
of corporate governance, legal affairs, business management, and
strategic decision-making. We expect that their diverse experience
and commitment to success will serve our company well going
forward."
About YS Biopharma
YS Biopharma is a global biopharmaceutical company dedicated to
discovering, developing, manufacturing, and commercializing new
generations of vaccines and therapeutic biologics for infectious
diseases and cancer. It has developed a proprietary PIKA®
immunomodulating technology platform and a series of preventive and
therapeutic biologics with a potential for improved Rabies,
Coronavirus, Hepatitis B, Influenza, and Shingles vaccines. YS
Biopharma operates in China,
the United States, Singapore and the
Philippines, and is led by a management team that combines
rich local expertise and global experience in the
bio-pharmaceutical industry. For more information, please visit
investor.ysbiopharm.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking statements'' within
the meaning of Section 27A of the Securities Act of 1933, as
amended, Section 21E of the Securities Exchange Act of 1934, as
amended, and the Private Securities Litigation Reform Act of 1995.
All statements other than statements of historical or current fact
included in this press release are forward-looking statements,
including but not limited to statements regarding the expected
growth of the Company, the development progress of all product
candidates, the progress and results of all clinical trials, the
Company's ability to source and retain talent, and the cash
position of the Company following the closing of the Business
Combination. Forward-looking statements may be identified by the
use of words such as "estimate," "plan," "project," "forecast,"
"intend," "will," "expect," "anticipate," "believe," "seek,"
"target" or other similar expressions that predict or indicate
future events or trends or that are not statements of historical
matters. These statements are based on various assumptions, whether
identified in this press release, and on the current expectations
of YS Biopharma's management and are not predictions of actual
performance.
These statements involve risks, uncertainties and other factors
that may cause actual results, levels of activity, performance, or
achievements to be materially different from those expressed or
implied by these forward-looking statements. Although YS Biopharma
believes that it has a reasonable basis for each forward-looking
statement contained in this press release, YS Biopharma cautions
you that these statements are based on a combination of facts and
factors currently known and projections of the future, which are
inherently uncertain. In addition, there are risks and
uncertainties described in the documents filed by YS Biopharma from
time to time with the U.S. Securities and Exchange Commission
("SEC"). These filings may identify and address other important
risks and uncertainties that could cause actual events and results
to differ materially from those contained in the forward-looking
statements.
YS Biopharma cannot assure you that the forward-looking
statements in this press release will prove to be accurate. These
forward-looking statements are subject to a number of risks and
uncertainties, including, among others, the outcome of any
potential litigation, government or regulatory proceedings, the
sales performance of the marketed vaccine product and the clinical
trial development results of the product candidates of YS
Biopharma, and other risks and uncertainties, including those
included under the heading "Risk Factors" in the post-effective
amendment No. 2 to Form F-1 filed with the SEC on January 23, 2024 which became effective on
January 25, 2024, and other filings
with the SEC. There may be additional risks that YS Biopharma does
not presently know or that YS Biopharma currently believes are
immaterial that could also cause actual results to differ from
those contained in the forward-looking statements. In light of the
significant uncertainties in these forward-looking statements,
nothing in this press release should be regarded as a
representation by any person that the forward-looking statements
set forth herein will be achieved or that any of the contemplated
results of such forward-looking statements will be achieved. The
forward-looking statements in this press release represent the
views of YS Biopharma as of the date of this press release.
Subsequent events and developments may cause those views to change.
However, while YS Biopharma may update these forward-looking
statements in the future, there is no current intention to do so,
except to the extent required by applicable law. You should,
therefore, not rely on these forward-looking statements as
representing the views of YS Biopharma as of any date subsequent to
the date of this press release. Except as may be required by law,
YS Biopharma does not undertake any duty to update these
forward-looking statements.
Investor Relations Contact
Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: YSBiopharma.IR@icrinc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ys-biopharma-announces-appointment-of-new-directors-302061795.html
SOURCE YS Biopharma Co., Ltd.
